in ,

Abbott Releases Interim Data from Clinical Studies on ID NOW COVID-19 Diagnostic

Abbott announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is “showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments”. The interim results are demonstrating ID NOW COVID-19 test performance is ≥94.7% in positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) when compared to two different lab-based PCR reference methods.

Data from this, as well as two other Abbott-sponsored studies – The Everett Clinic in Washington and an ongoing study of hospitalized and nursing home patients – suggest ID NOW performs best in patients tested earlier post symptom onset, when they are most likely to go for care. In these studies, ID NOW was used as intended with variations in patient populations based on the number of days a patient was tested after first experiencing symptoms.

Urgent Care Clinic Study

In 256 subjects enrolled to date, ID NOW has identified 29 of 29 positive samples (100% positive agreement) and 226 of 227 negative samples (99.6% negative agreement) when compared to a commonly-used lab-based molecular PCR assay (the Roche cobas® SARS-CoV-2 assay). 

In parallel, ID NOW has demonstrated 94.7% positive agreement and 98.6% negative agreement compared to the Centers for Disease Control (CDC) 2019-Novel Coronavirus (COVID-19) Real-Time RT-PCR Diagnostic Panel. In comparison, Roche has demonstrated 95.0% positive agreement and 98.7% negative agreement when compared to the CDC assay.

In these subjects, the mean number of days from symptom onset is 4.1 days with 90% of subjects tested within 7 days post symptom onset, when patients typically show up for care.  

The ongoing study is examining ID NOW COVID-19 test performance at five urgent care clinics (New Jersey, Tennessee, Louisiana, Texas and South Carolina). This is one of the first studies conducted on the ID NOW COVID-19 test in a real-world setting as it is intended to be used, compared with other studies that have used banked or retained samples.

The Everett Clinic Study

These interim results are consistent with results from a 955 subject study (763 symptomatic and 192 asymptomatic) presented last week in an Association for Molecular Pathology webinar by Yuan-Po Tu, M.D., of The Everett Clinic in Washington in a similar setting, which showed 91.3% positive agreement (sensitivity) and 100% negative agreement (specificity greater than 99.5% at the lower confidence limit) for ID NOW compared to lab-based PCR assays.

Study with Hospitalized and Nursing Home Patients

Abbott is conducting another ongoing study looking at ID NOW’s performance compared to two lab-based reference methods in nursing home and hospitalized settings later in post symptom onset than the populations in the urgent care and The Everett Clinic settings.

In an interim analysis, the mean number of days from symptom onset is 12.2 days with more than 68% presenting with ≥8 days post symptom onset. In comparison, the Everett study mean was 9.7 days post symptom onset and the urgent care clinic at 4.1 days post symptom onset.

In the hospitalized and nursing home analysis to date, ID NOW has shown 85.7% positive agreement and 97.6% negative agreement compared to the CDC assay, and 83.3% positive agreement and 96.5% negative agreement when compared to Hologic’s Panther Fusion® SARS-CoV-2 test. In comparison, the Hologic assay has demonstrated 91.8% positive agreement and 98.2% negative agreement when compared to the CDC assay.

Data from these studies suggest ID NOW performs best in people tested earlier after they first begin experiencing symptoms. This is consistent with a recent study published in the Annals of Internal Medicine, where researchers from Johns Hopkins found that even the most sensitive lab-based molecular tests can have false negatives when viral load levels are ramping down, near the end of the infection cycle when viral load winds down and patients may no longer be infectious.

Abbott will report full results from these studies when the studies and analyses are completed.

About the ID NOW Point-of-Care Molecular Platform

First introduced in 2014, ID NOW is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.

ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.

Using Machine Learning to Estimate COVID-19’s Seasonal Cycle

Top UK Virologists Review Latest Studies on SARS-CoV-2 Immunity